NorthView Acquisition Corp (NVAC)

[Devolution]

Peter O'Rourke (born January 3, 1966): 56 years old, currently Chairman of the Board of NorthView Acquisition Corp. Since December 2018, Mr. O’Rourke has served as Managing Partner at TCI Partners, a consulting firm focused on healthcare, aerospace and the public sector. From January 2017 to December 2018, Mr. O’Rourke served as the Acting Secretary and Chief of Staff of the Department of Veteran Affairs under Donald Trump. From May 2015 to July 2016, Mr. O’Rourke served as a principal of Calibre Systems, Inc., a consulting firm. Mr. O’Rourke also served both U.S. Navy and Air Force. Mr. O’Rourke received a Bachelor of Arts in Political Science from the University of Tennessee in Knoxville as well as a Master of Science in Logistics and Supply Chain Management from the United States Air Force’s Institute of Technology. He previously worked in various positions in government consulting, including as a congressional staffer for U.S. Representative Tom Latham, and he also served as the executive director of the Republican Party of Florida.

Peter joined Axim's Board of Director's on July 21, 2020.

In April, 2021, Peter formed the SPAC North View Acquisition Corp., which began selling shares in December of 2021. On November 7, 2022, NVAC announced its intent to merge with Profusa, a company pioneering a novel, innovative approach to accurately, efficiently, and easily measure various biochemistry markers in real time using the Lumee hydromicrofiber.

In the European Union, the Lumee Oxygen Platform is CE Marked (January 28, 2020). In the United States, the Lumee Oxygen Platform is an Investigational Device Limited by Federal Law to Investigational Use.

The goal of the merger is to turn Profusa into a publicly traded entity by the first quarter of 2023, and thereafter to seek FDA approval for Lumee in the United States.

Lumee is a biosensor micro fiber that can immediately measure oxygen levels, glucose levels, exposure to biochemicals, even early signs of influenza - almost any biomarker of interest found in intercellular fluid without the "old technology way" of pin pricking and drawing blood.

In 2016, DARPA and the U.S. Army Research Office (ARO) awarded Profusa a $7.5 million dollar grant to develop the company’s implantable biosensors for the simultaneous, continuous monitoring of multiple body sensors. Profusa has focused research and product development on providing real-time monitoring of a combat soldier’s health status to improve mission efficiency and overall performance, partnering with DARPA to create breakthrough technologies and capabilities for our national security.

Peter O'Rouke's close ties to the US government for years is a nice match for Profusa's Lumee Military applications and its ultimate movement into civilian applications.

Currently, devices such as Abbott's Freestyle Libre 2 and Dexcom's G6 are expensive and must be moved every two weeks (to prevent rejection by the body).